In a bid to break out of its pain therapy niche, Endo Pharmaceuticals agreed to pay up to $637 million to acquire Indevus Pharmaceuticals. Indevus shareholders get $370 million of that now and up to $267 million more if a series of discovery and commercial milestones are hit.According to Endo, the combined company will market nine therapies, including its pain therapies as well as Indevus’ Pagoclone for anxiety disorders and Trospim for overactive bladder. And Endo says it has identified some $40 million in cost savings.
Much of the upside of the deal will rest on the fate of Nebido, Indevus’ experimental therapy for hypogonadism. New data on the therapy will be sent to the FDA in the first half of 2009 as researchers seek an approval. Endo will pay $2 a share based on Nebido’s approval and performance.
This page has more details:
http://www.forbes.com/feeds/ap/2009/01/05/ap5881458.html
Nortel Networks Corp has sought legal advice to study a bankruptcy protection scenario in the event that its restructuring plan fails and has also been exploring potential assistance from the Canadian government, the Wall Street Journal reported. On the subject of legal advice for studying a bankruptcy scenario, the WSJ cited people familiar with the situation, while on the potential government aid scenario, it cited a person familiar with the situation. Nortel’s spokesperson said no bankruptcy filing was imminent though the Toronto-based company has engaged several advisors to plan ahead, the newspaper reported. Nortel could not be immediately reached for comment by media. Nortel, North America’s biggest maker of telephone equipment has lost billions of dollars and cut tens of thousands of jobs since the technology bubble burst at the beginning of this decade. The company has been unable to recover since then, with its problems exacerbated by the global economic slowdown. RBC Capital Markets analyst Mark Sue said in November the company faced significant liquidity concerns, with bankruptcy a distinct possibility before 2011.
